<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950807</url>
  </required_header>
  <id_info>
    <org_study_id>113073</org_study_id>
    <nct_id>NCT00950807</nct_id>
  </id_info>
  <brief_title>GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the dose response, safety, and pharmacokinetics of GSK573719 compared
      with placebo in subjects with COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is multicenter, randomized, double-blind, double-dummy, placebo-controlled, three-way
      cross-over, incomplete block design study to evaluation of 5 doses of GSK573719 administered
      once-daily and 3 doses of GSK573719 administered twice-daily over 14 days in subjects with
      COPD and will include tiotropium as an open-label active control. The pharmacokinetic profile
      of GSK573719 will also be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1, 2009</start_date>
  <completion_date type="Actual">March 15, 2010</completion_date>
  <primary_completion_date type="Actual">March 1, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Day 15 of Each Treatment Period</measure>
    <time_frame>Baseline and Day 15 of each treatment period (up to Study Day 71)</time_frame>
    <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 15 is defined as the value obtained 24 hours after the morning dose administered on Day 14. Analysis were performed using a mixed model with covariates of mean Baseline, period Baseline, treatment and period as fixed effects and participant as a random effect. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period; mean Baseline is the mean of the Baselines for each participant and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Change from Baseline for each treatment period is the trough FEV1 at Day 15 minus the Baseline value for that treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline (BL) in Weighted Mean FEV1 Over 0 to 24 Hours Obtained Post-dose on Day 14 of Each Treatment Period</measure>
    <time_frame>Baseline and Day 14 of each treatment period (TP; up to Study Day 70)</time_frame>
    <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The weighted mean FEV1 was calculated using 0-24 hour (h) post-dose measurements at Day 14 of each treatment period, which included pre-dose and post-dose 1, 3, 6, 9, 12, 13, 15, 18, 21 and 24 hours. Analysis performed using a mixed model with covariates mean BL, period BL, treatment and period as fixed effects and participant as a random effect. BL is the FEV1 value recorded pre-dose on Day 1 of each TP; mean BL is the mean of the BLs for each participant and period BL is the difference between the BL and the mean BL in each TP for each participant. Change from BL for each TP is the trough FEV1 at Day 15 minus the BL value for that TP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline (BL) in Serial FEV1 Over 0-28 Hours After the Morning Dose at Day 14 of Each Treatment Period</measure>
    <time_frame>Baseline and Day (D) 14 of each treatment period (TP; up to Study Day 70)</time_frame>
    <description>Serial FEV1 for OQ dosing is recorded at the pre-AM dose (time 0 h) and at 1, 3, 6, 9, 12,13, 15, 18, 21, 24 and 28 hs after the AM dose on D 14. For BID dosing, the 12 h AM dose corresponds to the pre-PM dose, 13 h AM dose corresponds to the 1 h PM dose, 15 h AM dose corresponds to the 3 h PM dose, 18 h AM corresponds to the 6 h PM dose, 21 h AM dose corresponds to 9 h PM dose, 24 h AM dose corresponds to the 12 h PM dose and 28 h AM dose corresponds to the 16 h PM dose in the table. Analysis performed using a mixed model with covariates of mean BL, period BL, trt, period, time, time by period BL interaction, time by mean BL interaction and time by trt interaction as fixed effects and par. as a random effect. BL is the FEV1 value recorded pre-dose on D 1 of each TP; mean BL is the mean of the BLs for each par. and period BL is the difference between the BL and the mean BL in each TP for each par. Change from BL for each TP is the trough FEV1 at Day 15 minus the BL value for that TP.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK573719 1000mcg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK573719 500mcg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK573719 250mcg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK573719 125mcg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK573719 62.5 mcg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK573719 250mcg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK573719 125mcg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK573719 62.5mcg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>long-acting muscarinic receptor antagonist; 18mcg once-daily</description>
    <arm_group_label>Tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive/ excipients only</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK573179</intervention_name>
    <description>GSK573179 investigational drug</description>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_label>Arm 8</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed and dated written informed consent prior to study participation

          -  Males or females of non-childbearing potential

          -  40 to 80 years of age

          -  COPD diagnosis

          -  10 pack-years history or greater of cigarette smoking

          -  Post-bronchodilator FEV1/FVC ratio of 0.70 or less

          -  Post-bronchodilator FEV1 of 35 to 70% of predicted normal

        Exclusion Criteria:

          -  Asthma

          -  Other significant respiratory disorders besides COPD, including alpha-1 deficiency

          -  Previous lung resection surgery

          -  Use of oral steroids or antibiotics for a COPD exacerbation within 6 weeks of
             screening

          -  Hospitalization for COPD or pneumonia within 3 months of screening

          -  Any significant disease that would put subject at risk through study participation

          -  BMI greater than 35

          -  Pacemaker

          -  Significantly abnormal ECG, Holter, or clinical lab finding (including Hepatitis B or
             C)

          -  Cancer

          -  Allergy or hypersensitivity to anticholinergics or inhaler excipients

          -  Diseases that would contra-indicate the use of anticholinergics

          -  Use of oral corticosteroids within 6 weeks of screening

          -  Use of long-acting beta-agonists within 48 hours of screening

          -  Use of tiotropium within 14 days of screening

          -  Use of theophyllines or anti-leukotrienes within 48 hours of screening

          -  Use of short-acting bronchodilators within 4 to 6 hours of screening

          -  Use of investigational medicines within 30 days of screening

          -  Use of high dose inhaled corticosteroids

          -  Use of long-term oxygen therapy, CPAP or NIPPV

          -  Previous use of GSK573719
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grosshansdorf</city>
        <state>Schleswig-Holstein</state>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012 Jul;106(7):970-9. doi: 10.1016/j.rmed.2012.03.012. Epub 2012 Apr 10.</citation>
    <PMID>22498110</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2009</study_first_submitted>
  <study_first_submitted_qc>July 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2009</study_first_posted>
  <results_first_submitted>January 16, 2014</results_first_submitted>
  <results_first_submitted_qc>January 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2014</results_first_posted>
  <disposition_first_submitted>March 22, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>March 22, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 29, 2012</disposition_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dose ranging</keyword>
  <keyword>Chronic Bronchitis</keyword>
  <keyword>Long-acting muscarinic antagonist</keyword>
  <keyword>cross-over</keyword>
  <keyword>COPD</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <keyword>anticholinergic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113073</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113073</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113073</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113073</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113073</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113073</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113073</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants (par.) who were eligible completed a 4- to 7-day Run-in period prior to randomization. The treatment (trt) phase was comprised of three 14-day trt periods. Par. were randomly assigned to receive a sequence of placebo and 2 of the 9 active trts over the trt phase. Participant Flow data are presented by treatment rather than sequence.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received matching placebo in the morning via dry powder inhaler (DPI) A and in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>UMEC 62.5 µg QD</title>
          <description>Participants received umeclidinium bromide (UMEC) 62.5 micrograms (µg) in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="P3">
          <title>UMEC 125 µg QD</title>
          <description>Participants received UMEC 125 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="P4">
          <title>UMEC 250 µg QD</title>
          <description>Participants received UMEC 250 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="P5">
          <title>UMEC 500 µg QD</title>
          <description>Participants received UMEC 500 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="P6">
          <title>UMEC 1000 µg QD</title>
          <description>Participants received UMEC 1000 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="P7">
          <title>UMEC 62.5 µg BID</title>
          <description>Participants received UMEC 62.5 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="P8">
          <title>UMEC 125 µg BID</title>
          <description>Participants received UMEC 125 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="P9">
          <title>UMEC 250 µg BID</title>
          <description>Participants received UMEC 250 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="P10">
          <title>Tiotropium 18 µg QD</title>
          <description>Participants received tiotropium bromide 18 µg in the morning via the HandiHaler and placebo in the evening via DPI B for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="13"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="13"/>
                <participants group_id="P10" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P2" count="13">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P3" count="13">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P4" count="11">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P5" count="11">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P6" count="11">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P7" count="10">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P8" count="13">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P9" count="11">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P10" count="13">Participants withdrawing during washout are counted under the last treatment taken.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P2" count="13">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P3" count="10">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P4" count="13">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P5" count="13">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P6" count="10">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P7" count="10">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P8" count="13">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P9" count="11">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P10" count="11">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="11"/>
                <participants group_id="P10" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="11"/>
                <participants group_id="P10" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P2" count="11">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P3" count="10">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P4" count="11">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P5" count="12">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P6" count="9">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P7" count="8">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P8" count="9">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P9" count="11">Participants withdrawing during washout are counted under the last treatment taken.</participants>
                <participants group_id="P10" count="11">Participants withdrawing during washout are counted under the last treatment taken.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P2" count="9">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P3" count="10">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P4" count="11">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P5" count="12">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P6" count="9">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P7" count="12">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P8" count="10">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P9" count="9">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
                <participants group_id="P10" count="11">By crossover design, participants were assigned to a different treatment arm in each period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="9"/>
                <participants group_id="P10" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Treatments</title>
          <description>The treatment phase was comprised of three 14-day treatment periods, each separated by a 10-14 day washout period. Participants were randomly assigned to receive a sequence of placebo and 2 of the 9 active treatments :
UMEC 62.5, 125, 250, 500, and 1000 µg QD, UMEC 62.5, 125, and 250 µg BID, tiotropium 18 µg QD.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" spread="8.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Day 15 of Each Treatment Period</title>
        <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 15 is defined as the value obtained 24 hours after the morning dose administered on Day 14. Analysis were performed using a mixed model with covariates of mean Baseline, period Baseline, treatment and period as fixed effects and participant as a random effect. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period; mean Baseline is the mean of the Baselines for each participant and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Change from Baseline for each treatment period is the trough FEV1 at Day 15 minus the Baseline value for that treatment period.</description>
        <time_frame>Baseline and Day 15 of each treatment period (up to Study Day 71)</time_frame>
        <population>Modified Intent-To-Treat (mITT) Population: all participants randomized to treatment who received at least one dose of study medication. All participants with &gt;=1 post-baseline assessment and non-missing covariate data are included in the analysis. The number of participants represents participants who provided data at Day 15.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo in the morning via dry powder inhaler (DPI) A and in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>UMEC 62.5 µg QD</title>
            <description>Participants received UMEC 62.5 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>UMEC 125 µg QD</title>
            <description>Participants received UMEC 125 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>UMEC 250 µg QD</title>
            <description>Participants received UMEC 250 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>UMEC 500 µg QD</title>
            <description>Participants received UMEC 500 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>UMEC 1000 µg QD</title>
            <description>Participants received UMEC 1000 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O7">
            <title>UMEC 62.5 µg BID</title>
            <description>Participants received UMEC 62.5 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O8">
            <title>UMEC 125 µg BID</title>
            <description>Participants received UMEC 125 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O9">
            <title>UMEC 250 µg BID</title>
            <description>Participants received UMEC 250 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O10">
            <title>Tio 18 µg QD</title>
            <description>Participants received tiotropium bromide 18 µg in the morning via the HandiHaler and placebo in the evening via DPI B for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Day 15 of Each Treatment Period</title>
          <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 15 is defined as the value obtained 24 hours after the morning dose administered on Day 14. Analysis were performed using a mixed model with covariates of mean Baseline, period Baseline, treatment and period as fixed effects and participant as a random effect. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period; mean Baseline is the mean of the Baselines for each participant and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Change from Baseline for each treatment period is the trough FEV1 at Day 15 minus the Baseline value for that treatment period.</description>
          <population>Modified Intent-To-Treat (mITT) Population: all participants randomized to treatment who received at least one dose of study medication. All participants with &gt;=1 post-baseline assessment and non-missing covariate data are included in the analysis. The number of participants represents participants who provided data at Day 15.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="29"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="32"/>
                <count group_id="O10" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.047" spread="0.017"/>
                    <measurement group_id="O2" value="0.081" spread="0.033"/>
                    <measurement group_id="O3" value="0.099" spread="0.034"/>
                    <measurement group_id="O4" value="0.048" spread="0.033"/>
                    <measurement group_id="O5" value="0.092" spread="0.032"/>
                    <measurement group_id="O6" value="0.138" spread="0.036"/>
                    <measurement group_id="O7" value="0.032" spread="0.035"/>
                    <measurement group_id="O8" value="0.087" spread="0.034"/>
                    <measurement group_id="O9" value="0.124" spread="0.034"/>
                    <measurement group_id="O10" value="0.058" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.128</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.060</ci_lower_limit>
            <ci_upper_limit>0.196</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.147</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.216</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.095</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.162</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.140</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.205</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.186</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.113</ci_lower_limit>
            <ci_upper_limit>0.259</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.079</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.008</ci_lower_limit>
            <ci_upper_limit>0.151</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.134</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.064</ci_lower_limit>
            <ci_upper_limit>0.204</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.172</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.101</ci_lower_limit>
            <ci_upper_limit>0.242</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.105</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.173</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline (BL) in Weighted Mean FEV1 Over 0 to 24 Hours Obtained Post-dose on Day 14 of Each Treatment Period</title>
        <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The weighted mean FEV1 was calculated using 0-24 hour (h) post-dose measurements at Day 14 of each treatment period, which included pre-dose and post-dose 1, 3, 6, 9, 12, 13, 15, 18, 21 and 24 hours. Analysis performed using a mixed model with covariates mean BL, period BL, treatment and period as fixed effects and participant as a random effect. BL is the FEV1 value recorded pre-dose on Day 1 of each TP; mean BL is the mean of the BLs for each participant and period BL is the difference between the BL and the mean BL in each TP for each participant. Change from BL for each TP is the trough FEV1 at Day 15 minus the BL value for that TP.</description>
        <time_frame>Baseline and Day 14 of each treatment period (TP; up to Study Day 70)</time_frame>
        <population>mITT Population. All participants with &gt;=1 post-Baseline assessment and non-missing covariate data are included in the analysis. The number of participants represents participants who provided data at Day 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo in the morning via dry powder inhaler (DPI) A and in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>UMEC 62.5 µg QD</title>
            <description>Participants received UMEC 62.5 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>UMEC 125 µg QD</title>
            <description>Participants received UMEC 125 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>UMEC 250 µg QD</title>
            <description>Participants received UMEC 250 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>UMEC 500 µg QD</title>
            <description>Participants received UMEC 500 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>UMEC 1000 µg QD</title>
            <description>Participants received UMEC 1000 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O7">
            <title>UMEC 62.5 µg BID</title>
            <description>Participants received UMEC 62.5 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O8">
            <title>UMEC 125 µg BID</title>
            <description>Participants received UMEC 125 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O9">
            <title>UMEC 250 µg BID</title>
            <description>Participants received UMEC 250 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O10">
            <title>Tio 18 µg QD</title>
            <description>Participants received tiotropium bromide 18 µg in the morning via the HandiHaler and placebo in the evening via DPI B for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (BL) in Weighted Mean FEV1 Over 0 to 24 Hours Obtained Post-dose on Day 14 of Each Treatment Period</title>
          <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The weighted mean FEV1 was calculated using 0-24 hour (h) post-dose measurements at Day 14 of each treatment period, which included pre-dose and post-dose 1, 3, 6, 9, 12, 13, 15, 18, 21 and 24 hours. Analysis performed using a mixed model with covariates mean BL, period BL, treatment and period as fixed effects and participant as a random effect. BL is the FEV1 value recorded pre-dose on Day 1 of each TP; mean BL is the mean of the BLs for each participant and period BL is the difference between the BL and the mean BL in each TP for each participant. Change from BL for each TP is the trough FEV1 at Day 15 minus the BL value for that TP.</description>
          <population>mITT Population. All participants with &gt;=1 post-Baseline assessment and non-missing covariate data are included in the analysis. The number of participants represents participants who provided data at Day 14.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="29"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.059" spread="0.014"/>
                    <measurement group_id="O2" value="0.085" spread="0.025"/>
                    <measurement group_id="O3" value="0.077" spread="0.025"/>
                    <measurement group_id="O4" value="0.077" spread="0.025"/>
                    <measurement group_id="O5" value="0.072" spread="0.024"/>
                    <measurement group_id="O6" value="0.080" spread="0.027"/>
                    <measurement group_id="O7" value="0.062" spread="0.026"/>
                    <measurement group_id="O8" value="0.083" spread="0.025"/>
                    <measurement group_id="O9" value="0.075" spread="0.026"/>
                    <measurement group_id="O10" value="0.069" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline (BL) in Serial FEV1 Over 0-28 Hours After the Morning Dose at Day 14 of Each Treatment Period</title>
        <description>Serial FEV1 for OQ dosing is recorded at the pre-AM dose (time 0 h) and at 1, 3, 6, 9, 12,13, 15, 18, 21, 24 and 28 hs after the AM dose on D 14. For BID dosing, the 12 h AM dose corresponds to the pre-PM dose, 13 h AM dose corresponds to the 1 h PM dose, 15 h AM dose corresponds to the 3 h PM dose, 18 h AM corresponds to the 6 h PM dose, 21 h AM dose corresponds to 9 h PM dose, 24 h AM dose corresponds to the 12 h PM dose and 28 h AM dose corresponds to the 16 h PM dose in the table. Analysis performed using a mixed model with covariates of mean BL, period BL, trt, period, time, time by period BL interaction, time by mean BL interaction and time by trt interaction as fixed effects and par. as a random effect. BL is the FEV1 value recorded pre-dose on D 1 of each TP; mean BL is the mean of the BLs for each par. and period BL is the difference between the BL and the mean BL in each TP for each par. Change from BL for each TP is the trough FEV1 at Day 15 minus the BL value for that TP.</description>
        <time_frame>Baseline and Day (D) 14 of each treatment period (TP; up to Study Day 70)</time_frame>
        <population>mITT Population. All par. with &gt;=1 post-BL assessment and non-missing covariate data are included in the analysis. Different par. may have been analyzed at different time points (n=X, X, X, X in the category titles), so the overall number of par. analyzed reflects everyone in the mITT Population with data available at &gt;=1 time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo in the morning via dry powder inhaler (DPI) A and in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>UMEC 62.5 µg QD</title>
            <description>Participants received UMEC 62.5 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>UMEC 125 µg QD</title>
            <description>Participants received UMEC 125 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>UMEC 250 µg QD</title>
            <description>Participants received UMEC 250 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>UMEC 500 µg QD</title>
            <description>Participants received UMEC 500 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>UMEC 1000 µg QD</title>
            <description>Participants received UMEC 1000 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O7">
            <title>UMEC 62.5 µg BID</title>
            <description>Participants received UMEC 62.5 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O8">
            <title>UMEC 125 µg BID</title>
            <description>Participants received UMEC 125 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O9">
            <title>UMEC 250 µg BID</title>
            <description>Participants received UMEC 250 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
          </group>
          <group group_id="O10">
            <title>Tio 18 µg QD</title>
            <description>Participants received tiotropium bromide 18 µg in the morning via the HandiHaler and placebo in the evening via DPI B for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (BL) in Serial FEV1 Over 0-28 Hours After the Morning Dose at Day 14 of Each Treatment Period</title>
          <description>Serial FEV1 for OQ dosing is recorded at the pre-AM dose (time 0 h) and at 1, 3, 6, 9, 12,13, 15, 18, 21, 24 and 28 hs after the AM dose on D 14. For BID dosing, the 12 h AM dose corresponds to the pre-PM dose, 13 h AM dose corresponds to the 1 h PM dose, 15 h AM dose corresponds to the 3 h PM dose, 18 h AM corresponds to the 6 h PM dose, 21 h AM dose corresponds to 9 h PM dose, 24 h AM dose corresponds to the 12 h PM dose and 28 h AM dose corresponds to the 16 h PM dose in the table. Analysis performed using a mixed model with covariates of mean BL, period BL, trt, period, time, time by period BL interaction, time by mean BL interaction and time by trt interaction as fixed effects and par. as a random effect. BL is the FEV1 value recorded pre-dose on D 1 of each TP; mean BL is the mean of the BLs for each par. and period BL is the difference between the BL and the mean BL in each TP for each par. Change from BL for each TP is the trough FEV1 at Day 15 minus the BL value for that TP.</description>
          <population>mITT Population. All par. with &gt;=1 post-BL assessment and non-missing covariate data are included in the analysis. Different par. may have been analyzed at different time points (n=X, X, X, X in the category titles), so the overall number of par. analyzed reflects everyone in the mITT Population with data available at &gt;=1 time point.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="32"/>
                <count group_id="O10" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-AM dose, n=152,34,33,35,37,30,32,33,32,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.016"/>
                    <measurement group_id="O2" value="0.140" spread="0.031"/>
                    <measurement group_id="O3" value="0.101" spread="0.032"/>
                    <measurement group_id="O4" value="0.167" spread="0.031"/>
                    <measurement group_id="O5" value="0.095" spread="0.030"/>
                    <measurement group_id="O6" value="0.120" spread="0.033"/>
                    <measurement group_id="O7" value="0.096" spread="0.032"/>
                    <measurement group_id="O8" value="0.139" spread="0.032"/>
                    <measurement group_id="O9" value="0.152" spread="0.032"/>
                    <measurement group_id="O10" value="0.129" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour AM, n=151,34,31,35,37,29,32,33,32,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022" spread="0.018"/>
                    <measurement group_id="O2" value="0.246" spread="0.035"/>
                    <measurement group_id="O3" value="0.164" spread="0.037"/>
                    <measurement group_id="O4" value="0.140" spread="0.035"/>
                    <measurement group_id="O5" value="0.056" spread="0.034"/>
                    <measurement group_id="O6" value="0.072" spread="0.038"/>
                    <measurement group_id="O7" value="0.159" spread="0.037"/>
                    <measurement group_id="O8" value="0.132" spread="0.036"/>
                    <measurement group_id="O9" value="0.142" spread="0.037"/>
                    <measurement group_id="O10" value="0.229" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hour AM, n=150,34,32,35,37,29,31,33,32,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="0.017"/>
                    <measurement group_id="O2" value="0.157" spread="0.034"/>
                    <measurement group_id="O3" value="0.158" spread="0.035"/>
                    <measurement group_id="O4" value="0.222" spread="0.034"/>
                    <measurement group_id="O5" value="0.142" spread="0.033"/>
                    <measurement group_id="O6" value="0.148" spread="0.037"/>
                    <measurement group_id="O7" value="0.153" spread="0.036"/>
                    <measurement group_id="O8" value="0.112" spread="0.035"/>
                    <measurement group_id="O9" value="0.153" spread="0.036"/>
                    <measurement group_id="O10" value="0.191" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hour AM, n=151,34,33,35,37,30,32,33,31,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.016"/>
                    <measurement group_id="O2" value="0.137" spread="0.031"/>
                    <measurement group_id="O3" value="0.114" spread="0.032"/>
                    <measurement group_id="O4" value="0.149" spread="0.031"/>
                    <measurement group_id="O5" value="0.120" spread="0.030"/>
                    <measurement group_id="O6" value="0.105" spread="0.034"/>
                    <measurement group_id="O7" value="0.090" spread="0.033"/>
                    <measurement group_id="O8" value="0.100" spread="0.032"/>
                    <measurement group_id="O9" value="0.141" spread="0.033"/>
                    <measurement group_id="O10" value="0.152" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 hour AM, n=149,33,33,34,37,30,31,32,32,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.033" spread="0.016"/>
                    <measurement group_id="O2" value="0.121" spread="0.033"/>
                    <measurement group_id="O3" value="0.077" spread="0.033"/>
                    <measurement group_id="O4" value="0.123" spread="0.032"/>
                    <measurement group_id="O5" value="0.118" spread="0.031"/>
                    <measurement group_id="O6" value="0.076" spread="0.035"/>
                    <measurement group_id="O7" value="0.105" spread="0.034"/>
                    <measurement group_id="O8" value="0.104" spread="0.033"/>
                    <measurement group_id="O9" value="0.099" spread="0.034"/>
                    <measurement group_id="O10" value="0.105" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour AM, n=150,34,33,34,37,30,31,32,32,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.068" spread="0.018"/>
                    <measurement group_id="O2" value="0.087" spread="0.035"/>
                    <measurement group_id="O3" value="0.083" spread="0.036"/>
                    <measurement group_id="O4" value="0.084" spread="0.035"/>
                    <measurement group_id="O5" value="0.096" spread="0.034"/>
                    <measurement group_id="O6" value="0.074" spread="0.038"/>
                    <measurement group_id="O7" value="0.058" spread="0.037"/>
                    <measurement group_id="O8" value="0.099" spread="0.036"/>
                    <measurement group_id="O9" value="0.074" spread="0.036"/>
                    <measurement group_id="O10" value="0.153" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 hour AM, n=147,33,33,35,37,29,31,33,32,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.082" spread="0.016"/>
                    <measurement group_id="O2" value="0.071" spread="0.031"/>
                    <measurement group_id="O3" value="0.077" spread="0.031"/>
                    <measurement group_id="O4" value="0.071" spread="0.031"/>
                    <measurement group_id="O5" value="0.103" spread="0.030"/>
                    <measurement group_id="O6" value="0.096" spread="0.033"/>
                    <measurement group_id="O7" value="0.066" spread="0.032"/>
                    <measurement group_id="O8" value="0.018" spread="0.032"/>
                    <measurement group_id="O9" value="0.048" spread="0.032"/>
                    <measurement group_id="O10" value="0.065" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 hour AM, n=151,34,33,35,37,29,30,33,32,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.085" spread="0.016"/>
                    <measurement group_id="O2" value="0.074" spread="0.031"/>
                    <measurement group_id="O3" value="0.051" spread="0.032"/>
                    <measurement group_id="O4" value="0.069" spread="0.031"/>
                    <measurement group_id="O5" value="0.038" spread="0.030"/>
                    <measurement group_id="O6" value="0.050" spread="0.033"/>
                    <measurement group_id="O7" value="0.085" spread="0.033"/>
                    <measurement group_id="O8" value="0.054" spread="0.032"/>
                    <measurement group_id="O9" value="0.096" spread="0.032"/>
                    <measurement group_id="O10" value="0.036" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 hour AM, n=148,33,33,35,36,29,31,33,32,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.145" spread="0.016"/>
                    <measurement group_id="O2" value="-0.053" spread="0.033"/>
                    <measurement group_id="O3" value="0.002" spread="0.033"/>
                    <measurement group_id="O4" value="-0.018" spread="0.032"/>
                    <measurement group_id="O5" value="-0.007" spread="0.031"/>
                    <measurement group_id="O6" value="0.001" spread="0.035"/>
                    <measurement group_id="O7" value="-0.020" spread="0.034"/>
                    <measurement group_id="O8" value="0.016" spread="0.033"/>
                    <measurement group_id="O9" value="-0.048" spread="0.033"/>
                    <measurement group_id="O10" value="-0.097" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 hour AM, n=150,34,33,35,37,29,29,33,32,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.147" spread="0.017"/>
                    <measurement group_id="O2" value="0.009" spread="0.034"/>
                    <measurement group_id="O3" value="0.035" spread="0.034"/>
                    <measurement group_id="O4" value="-0.036" spread="0.034"/>
                    <measurement group_id="O5" value="0.004" spread="0.033"/>
                    <measurement group_id="O6" value="0.006" spread="0.037"/>
                    <measurement group_id="O7" value="-0.059" spread="0.036"/>
                    <measurement group_id="O8" value="0.029" spread="0.035"/>
                    <measurement group_id="O9" value="-0.005" spread="0.035"/>
                    <measurement group_id="O10" value="-0.060" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour AM, n=150,34,33,35,37,29,31,33,32,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.051" spread="0.017"/>
                    <measurement group_id="O2" value="0.067" spread="0.033"/>
                    <measurement group_id="O3" value="0.093" spread="0.034"/>
                    <measurement group_id="O4" value="0.045" spread="0.033"/>
                    <measurement group_id="O5" value="0.088" spread="0.032"/>
                    <measurement group_id="O6" value="0.142" spread="0.036"/>
                    <measurement group_id="O7" value="0.021" spread="0.035"/>
                    <measurement group_id="O8" value="0.091" spread="0.034"/>
                    <measurement group_id="O9" value="0.139" spread="0.035"/>
                    <measurement group_id="O10" value="0.047" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 hour AM, n=145,34,33,35,37,29,31,33,32,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.065" spread="0.018"/>
                    <measurement group_id="O2" value="0.179" spread="0.035"/>
                    <measurement group_id="O3" value="0.177" spread="0.036"/>
                    <measurement group_id="O4" value="0.212" spread="0.035"/>
                    <measurement group_id="O5" value="0.143" spread="0.034"/>
                    <measurement group_id="O6" value="0.191" spread="0.038"/>
                    <measurement group_id="O7" value="0.164" spread="0.037"/>
                    <measurement group_id="O8" value="0.219" spread="0.036"/>
                    <measurement group_id="O9" value="0.185" spread="0.037"/>
                    <measurement group_id="O10" value="0.108" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication up to 10 weeks.</time_frame>
      <desc>On-treatment AEs and non-serious AEs are reported for members of the mITT Population, comprised of all participants who were randomized to treatment and who had received at least one dose of randomized study medication during treatment period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received matching placebo in the morning via dry powder inhaler (DPI) A and in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="E2">
          <title>UMEC 62.5 µg QD</title>
          <description>Participants received UMEC 62.5 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="E3">
          <title>UMEC 125 µg QD</title>
          <description>Participants received UMEC 125 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="E4">
          <title>UMEC 250 µg QD</title>
          <description>Participants received UMEC 250 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="E5">
          <title>UMEC 500 µg QD</title>
          <description>Participants received UMEC 500 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="E6">
          <title>UMEC 1000 µg QD</title>
          <description>Participants received UMEC 1000 µg in the morning via DPI A and placebo in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="E7">
          <title>UMEC 62.5 µg BID</title>
          <description>Participants received UMEC 62.5 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="E8">
          <title>UMEC 125 µg BID</title>
          <description>Participants received UMEC 125 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="E9">
          <title>UMEC 250 µg BID</title>
          <description>Participants received UMEC 250 µg in the morning via DPI A and in the evening via DPI B for 14 days.</description>
        </group>
        <group group_id="E10">
          <title>Tio 18 µg QD</title>
          <description>Participants received tiotropium bromide 18 µg in the morning via the HandiHaler and placebo in the evening via DPI B for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

